MABLINK BIOSCIENCE
Mablink Bioscience is a biotechnology company specialized in the development of a new class of cancer drugs, called Antibody Drug Conjugate (ADC).
MABLINK BIOSCIENCE
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2018-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.mablink.com
Total Employee:
1+
Status:
Active
Total Funding:
4 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Faze Medicines
Faze Medicines is a biotechnology company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Pertinence Invest
Pertinence Invest investment in Seed Round - Mablink Bioscience
Elaia
Elaia investment in Seed Round - Mablink Bioscience
Simba Santé
Simba Santé investment in Seed Round - Mablink Bioscience
Fournier-Majoie
Fournier-Majoie investment in Seed Round - Mablink Bioscience
Crédit Agricole
Crédit Agricole investment in Seed Round - Mablink Bioscience
Sham Innovation Santé
Sham Innovation Santé investment in Seed Round - Mablink Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-01 | Mablink Bioscience announces appointment of its Chief Development Officer |
Official Site Inspections
http://www.mablink.com Semrush global rank: 5.4 M Semrush visits lastest month: 1.56 K
- Host name: omics-docs.am.lilly.com
- IP address: 40.255.173.239
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Mablink Bioscience"
Mablink Bioscience - Crunchbase Company Profile
Organization. Mablink Bioscience . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Mablink Bioscience is a biotechnology company. ... Mablink Bioscience may …See details»
Mablink Bioscience SAS - Drug pipelines, Patents, Clinical trials
Dec 21, 2024 Explore Mablink Bioscience SAS with its drug pipeline, therapeutic area, technology platform, 25 news, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, …See details»
Mablink Company Profile 2024: Valuation, Investors, …
Mablink General Information Description. Operator of a biotechnology company intended to develop antibody-drug-conjugates drugs to fight cancer. The company helps to design homogenous, plasma-stable conjugates with a high drug …See details»
Mablink Bioscience - Overview, News & Similar companies
Oct 13, 2022 Who is Mablink Bioscience. Mablink Bioscience is a French-based biotechnology company founded in 2018, specialized in the development of a new class of cancer drugs, …See details»
Mablink Bioscience Information - RocketReach
Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates …See details»
Mablink Bioscience Company Profile - Office Locations ... - Craft
Mablink Bioscience has 5 employees across 2 locations and $4.84 m in total funding,. See insights on Mablink Bioscience including office locations, competitors, revenue, financials, …See details»
Mablink Bioscience Company Overview, Contact Details
Oct 14, 2022 Target Market Expansion Mablink Bioscience, with its innovative Antibody-Drug Conjugates (ADC) masking technology in the fight against cancer, presents a strategic …See details»
Mablink Bioscience - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Oct 14, 2022: Series A - …See details»
MABLINK BIOSCIENCE Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MABLINK BIOSCIENCE of LYON, AUVERGNE RHONE ALPES. Get the latest business insights from …See details»
Mablink Bioscience - Merieux Partners
Mablink Bioscience The company is developing an innovative chemical masking platform for the optimization of antibody conjugate drug candidates (ADCs) for the treatment of cancer. The …See details»
Mablink Bioscience announces a Series A funding round led by
Mablink Bioscience is a biotechnology company that seeks to bring new and better treatment options to cancer patients with unmet needs. The company is developing the next generation …See details»
Mablink Bioscience, the next generation ADC company, raises
Apr 27, 2021 Mablink Bioscience's platform presents a best-in-class approach and has the potential to deliver the next wave of innovation to the promising field of antibody drug …See details»
Mablink Bioscience - Contacts, Employees, Board Members
Organization. Mablink Bioscience . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Mablink Bioscience has 3 current employee profiles, including …See details»
Mablink Bioscience Company Information - Funding, Investors
The company Mablink Bioscience has raised a total of $34.92m in funding over 2 rounds. Key Insights: Series A: $30.14m; Seed: $4.78m; 2021. Mablink Bioscience Seed (2021, $4M) …See details»
Mablink Bioscience Enters an Agreement to be Acquired by
Oct 18, 2023 For more information, please visit https://mablink.com. Press Contacts: Lilly: Lauren Cohen 617.678.2067. [email protected]. Attachment. Mablink Bioscience …See details»
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Oct 18, 2023 The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates. Lyon, …See details»
Mablink Bioscience enters an agreement to be acquired by Lilly
Lyon, France – October 18, 2023 - Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via …See details»
Mablink Bioscience, the next generation ADC company, raises €4 …
Apr 27, 2021 Mablink Bioscience's platform presents a best-in-class approach and has the potential to deliver the next wave of innovation to the promising field of antibody drug …See details»
Mablink Bioscience Announces a €31 Million Series A Funding …
Oct 14, 2022 Mablink Bioscience ("Mablink"), a biotechnology company aiming to transform cancer therapy using next-generation antibody-drug conjugates (ADCs), announced today that …See details»
Mablink Bioscience — Sofinnova Partners
Mablink Bioscience is developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink's patented hydrophilic drug-linker technology …See details»